Eurofins Optimed
Gières, 38610, France
NCT Number: NCT02534064
The purpose of this study is to evaluate the effect of daily consumption of one or two CALIN+ pot(s) versus no intake of product, after 4, 8, 12 and 16 weeks, on the evolution of the serum concentration of 25-hydroxy vitamin D (25OHD) (D2 + D3) in postmenopausal women.
Looking for future studies?
Notify Me55 year–75 year
Female
Interventional
Not applicable
Gières, 38610, France
The active form of vitamin D is produced by skin when it is exposed to ultraviolet-B (UVB) rays. However, because of our sedentary lifestyle and to the low sun exposure during winter, the vitamin D status is most frequently deficient. Hence the consumption of enriched food could be an efficient strategy to improve vitamin D status.
The current recommendation for vitamin D intake is 20 µg per day for adults (19-50 yo) and between 25 and 37.5 µg per day for people over 50 years old according to the French National Medicine Academy. However, the recommended daily allowance (RDA) in France for vitamin D is limited to 5 µg corresponding to the maximum enrichment allowed in a food product. The current study is designed to evaluate if a daily consumption of two CALIN+ yogurts enriched with 5µg of vitamin D is sufficient to improve the vitamin D status in postmenopausal women.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Consumption of 2 CALIN+ pots per day during 16 weeks and follow up without product intake during 8 weeks.
Time frame: serum 25OHD (D2 + D3) concentration will be evaluated at 4, 8, 12 and 16 weeks
Time frame: Evolution after 16 weeks consumption period
Serum (ParaThyroid Hormone) PTH level
Time frame: Evolution after 16 weeks consumption period
Serum calcium level
Time frame: Evolution after 16 weeks consumption period
Serum 25OHD (D2 + D3) level
Time frame: Evolution after 16 weeks consumption period
Diastolic / systolic blood pressures
Time frame: Evolution after 16 weeks consumption period
Weight (kg)
Time frame: Evolution after 16 weeks consumption period
Waist circumference (com)
Time frame: over two months
Rate constant
Time frame: Evolution over 8 weeks consumption period for women included in study during winter (before March 1, 2015)
Serum 25OHD (D2 + D3) level
Time frame: Evolution over 8 weeks consumption period for women included in study during winter (before March 1, 2015)
Serum ParaThyroid Hormone (PTH) level
Time frame: Evolution over 8 weeks consumption period for women included in study during winter (before March 1, 2015)
Serum calcium level
Time frame: Evolution over 8 weeks consumption period for women included in study during winter (before March 1, 2015)
Diastolic/systolic blood pressures (mm/Hg)
Time frame: Evolution over 8 weeks consumption period for women included in study during winter (before March 1, 2015)
Weight (kg)
Time frame: Evolution over 8 weeks consumption period for women included in study during winter (before March 1, 2015)
Waist circumference (cm)
Time frame: Evolution over the 2 months follow up period
Serum levels of 25OHD (D2 + D3),
Time frame: Evolution over the 2 months follow up period
Serum ParaThyroid Hormone (PTH) level
Time frame: 4 months and 6 months
Assessment of sun exposure and dietary vitamin D intake using the Garabedian questionnaire
Time frame: over the 16-week consumption period and over the first 8 weeks consumption for women included in the study during the winter season, i.e. before March 1, 2015.
Assessment of calcium intake using a simplified calcium questionnaire
Time frame: up to 20 weeks
Number of consumed yogurt per day
Time frame: up to 20 weeks
Change from baseline in acceptability score (0: do not agree at all; 10: agree completely)
Yoplait France SAS
Industry
Effect of the Consumption of Yogurt Fortified in Calcium and Vitamin D on the Circulating Levels of 25OHD in Postmenopausal Women
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05372224
Avitaminosis, Bone Diseases
Mexico City, Gustavo A. Madero, Mexico
View Trial DetailsNCT02815566
Bone Diseases, Bone Diseases, Metabolic
Vancouver, British Columbia, Canada
View Trial DetailsNCT03331536
Bariatric Surgery, Bone Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT00697463
Bone Diseases, Bone Diseases, Metabolic
Omaha, Nebraska, United States
View Trial Details